Simple changes in care reduced heart exposure during lung cancer radiation treatment

By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 

1:01 PM

Author | Anna Megdell

women doc looking ay xray up on bright board
Getty Images

Radiation to the heart during treatment for locally advanced lung cancer is associated with an increased risk of major adverse cardiac events within the first two years following treatment. The higher the cardiac dose exposure, the higher the risk of a cardiac event.

A team at the University of Michigan Health Rogel Cancer Center, in partnership with the statewide Michigan Radiation Oncology Quality Consortium, or MROQC, lung cancer collaborative, co-led by Shruti Jolly, M.D., and Peter Paximadis, M.D., of Spectrum Health Lakeland in St. Joseph, Michigan, found that raising awareness about the risk of radiation exposure to the heart and standardizing cardiac exposure limits reduced the average dose to the heart by 15% and reduced the number of patients receiving the highest heart doses by half without minimizing tumor treatment or increasing dosage to other at-risk organs in the chest.

The study, featured in Practical Radiation Oncology, assessed the effectiveness of this education across MROQC. The statewide consortium is a comprehensive clinical and physics database to support quality improvement throughout Michigan, funded through support from Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships Program.

The educational program involved spreading awareness of new data coming out about cardiac radiation exposure in NSCLC patients and adjusting cardiac goals within MROQC accordingly. Daniel Herr, M.D., Ph.D., radiation oncology resident and first author of this study, says that increased education and awareness regarding the implication of radiation to the heart had a meaningful impact on clinical practice.

"This study is evidence that relatively simple interventions, when properly targeted, can be effective at improving patient care," Herr said. "It's more evidence that having a large quality consortium like MROQC is a real advantage in terms of improving the quality of care that patients throughout the state of Michigan receive."

Additional authors include Kim A. Hochstedler, M.S., Huiying Yin, M.S., Robert T. Dess, M.D., Martha Matuszak, Ph.D., Margaret Grubb, M.S., Michael Dominello, M.D., Benjamin Movsas, M.D., Larry L. Kestin, M.D., Derek Bergsma, M.D., Aleksandar F. Dragovic, M.D., Inga S. Grills, M.D., James A. Hayman, M.D., Peter Paximadis, M.D., Matthew Schipper, Ph.D., Shruti Jolly, M.D.

Paper cited: "Effect of Education and Standardization of Cardiac Dose Constraints on Heart Dose in Patients With Lung Cancer Receiving Definitive Radiation Therapy Across a Statewide Consortium," Practical Radiation Oncology. DOI: 10.1016/j.prro.2022.01.002


More Articles About: Lab Notes Cancer Research Cancer Treatment Radiation Oncology lung cancer Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories blue purple cell dots on white background all over in different patterns
Health Lab
Research finds possible therapies to target oncogenic transcription factors in multiple cancer types
A study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.
iv chemo bags
Health Lab
Drug-chemo combo increases cancer treatment efficacy
A study finds giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain metastases from triple negative breast cancer
close up photo of yellow pills lined up on a bright blue matt
Health Lab
New drug candidate blocks resistance to cancer therapies
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance.
two women, one older one younger, looking concerned listening to a provider across from them with back to camera
Health Lab
Many breast cancer survivors don't receive genetic testing, despite being eligible
As cancer treatment and survivorship care relies more on understanding the genetic make up of an individual’s tumor, a study from the University of Michigan Health Rogel Cancer Center finds that many breast cancer survivors who meet criteria for genetic counseling and testing are not receiving it.
Cancer cell microscopic, colored yellow
Health Lab
Researchers find common immune system mechanism between pregnancy, cancer
Researchers find common immune system mechanism between pregnancy, cancer
light lights seen on dark navy screen
Health Lab
Researchers identify novel biomarker linked to renal cancer recurrence
Researchers from the University of Michigan Health Rogel Cancer Center have discovered a biomarker that could help identify which renal cancer patients have a higher risk of recurrence.